Thomson Horstmann & Bryant Inc. held its position in Omnicell, Inc. (NASDAQ:OMCL) during the first quarter, Holdings Channel reports. The fund owned 140,958 shares of the company’s stock at the end of the first quarter. Thomson Horstmann & Bryant Inc. owned about 0.38% of Omnicell worth $5,729,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in OMCL. 1st Global Advisors Inc. bought a new position in Omnicell during the third quarter worth $205,000. Nationwide Fund Advisors raised its position in shares of Omnicell by 9.9% in the third quarter. Nationwide Fund Advisors now owns 227,503 shares of the company’s stock worth $8,713,000 after buying an additional 20,446 shares during the last quarter. Louisiana State Employees Retirement System raised its position in shares of Omnicell by 0.6% in the third quarter. Louisiana State Employees Retirement System now owns 16,000 shares of the company’s stock worth $613,000 after buying an additional 100 shares during the last quarter. Juncture Wealth Strategies LLC raised its position in shares of Omnicell by 3.2% in the third quarter. Juncture Wealth Strategies LLC now owns 28,048 shares of the company’s stock worth $1,074,000 after buying an additional 860 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust raised its position in shares of Omnicell by 7.6% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 124,157 shares of the company’s stock worth $4,755,000 after buying an additional 8,740 shares during the last quarter. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Shares of Omnicell, Inc. (NASDAQ:OMCL) traded down 1.717% during trading on Friday, hitting $40.075. The company’s stock had a trading volume of 442,954 shares. The firm’s 50 day moving average is $39.49 and its 200-day moving average is $36.06. Omnicell, Inc. has a 1-year low of $28.76 and a 1-year high of $41.15. The company has a market capitalization of $1.48 billion, a P/E ratio of 2357.353 and a beta of 0.76.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Wednesday, February 15th. The company reported $0.37 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.41 by $0.04. The company had revenue of $171.97 million for the quarter, compared to the consensus estimate of $179.28 million. Omnicell had a return on equity of 10.74% and a net margin of 1.24%. Analysts forecast that Omnicell, Inc. will post $1.36 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Thomson Horstmann & Bryant Inc. Holds Stake in Omnicell, Inc. (OMCL)” was reported by Financial Market News and is the property of of Financial Market News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at http://www.financial-market-news.com/thomson-horstmann-bryant-inc-holds-stake-in-omnicell-inc-omcl/1405994/.

A number of equities analysts have issued reports on the company. Piper Jaffray Companies lowered Omnicell from an “overweight” rating to a “neutral” rating in a research report on Friday. Cantor Fitzgerald assumed coverage on Omnicell in a research report on Thursday, January 5th. They issued an “overweight” rating and a $40.00 target price on the stock. TheStreet raised Omnicell from a “c” rating to a “b-” rating in a research report on Wednesday, February 15th. Zacks Investment Research raised Omnicell from a “sell” rating to a “hold” rating in a research report on Wednesday, March 1st. Finally, Dougherty & Co assumed coverage on Omnicell in a research report on Thursday, January 19th. They issued a “buy” rating and a $44.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $44.71.

In other Omnicell news, Director Sara J. White sold 3,443 shares of Omnicell stock in a transaction on Tuesday, February 21st. The stock was sold at an average price of $38.06, for a total value of $131,040.58. Following the completion of the transaction, the director now owns 43,214 shares in the company, valued at approximately $1,644,724.84. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Gary S. Petersmeyer sold 2,658 shares of Omnicell stock in a transaction on Friday, March 10th. The shares were sold at an average price of $37.45, for a total value of $99,542.10. Following the completion of the transaction, the director now owns 20,085 shares of the company’s stock, valued at approximately $752,183.25. The disclosure for this sale can be found here. 3.75% of the stock is owned by company insiders.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

5 Day Chart for NASDAQ:OMCL

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.